Byron Myers Sells 10,000 Shares of Inogen, Inc (INGN) Stock
Inogen, Inc (NASDAQ:INGN) EVP Byron Myers sold 10,000 shares of the business’s stock in a transaction dated Monday, December 11th. The shares were sold at an average price of $116.81, for a total transaction of $1,168,100.00. Following the completion of the transaction, the executive vice president now owns 48,600 shares in the company, valued at approximately $5,676,966. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.
Byron Myers also recently made the following trade(s):
- On Friday, November 17th, Byron Myers sold 35,000 shares of Inogen stock. The shares were sold at an average price of $116.77, for a total transaction of $4,086,950.00.
Inogen, Inc (NASDAQ:INGN) opened at $121.22 on Thursday. Inogen, Inc has a 52-week low of $62.69 and a 52-week high of $130.05. The stock has a market cap of $2,476.27, a PE ratio of 96.46, a P/E/G ratio of 4.99 and a beta of 1.13.
Inogen (NASDAQ:INGN) last announced its quarterly earnings results on Tuesday, November 7th. The medical technology company reported $0.33 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.29 by $0.04. Inogen had a net margin of 11.36% and a return on equity of 13.37%. The company had revenue of $69.00 million for the quarter, compared to analysts’ expectations of $63.55 million. During the same quarter in the previous year, the company earned $0.25 earnings per share. Inogen’s quarterly revenue was up 26.8% on a year-over-year basis. analysts expect that Inogen, Inc will post 1.19 earnings per share for the current fiscal year.
Several hedge funds and other institutional investors have recently made changes to their positions in INGN. Schroder Investment Management Group purchased a new position in shares of Inogen during the second quarter valued at about $132,000. Ameritas Investment Partners Inc. increased its position in shares of Inogen by 6.1% during the second quarter. Ameritas Investment Partners Inc. now owns 1,495 shares of the medical technology company’s stock valued at $143,000 after buying an additional 86 shares during the period. Sei Investments Co. increased its position in shares of Inogen by 38.1% during the second quarter. Sei Investments Co. now owns 1,606 shares of the medical technology company’s stock valued at $153,000 after buying an additional 443 shares during the period. Victory Capital Management Inc. increased its position in shares of Inogen by 17.8% during the second quarter. Victory Capital Management Inc. now owns 2,036 shares of the medical technology company’s stock valued at $194,000 after buying an additional 307 shares during the period. Finally, Pinebridge Investments L.P. increased its position in shares of Inogen by 1.6% during the second quarter. Pinebridge Investments L.P. now owns 2,143 shares of the medical technology company’s stock valued at $204,000 after buying an additional 33 shares during the period.
A number of equities analysts have issued reports on INGN shares. Leerink Swann restated an “outperform” rating and issued a $120.00 price objective (up previously from $115.00) on shares of Inogen in a research report on Wednesday, November 8th. Piper Jaffray Companies restated a “hold” rating and issued a $90.00 price objective on shares of Inogen in a research report on Tuesday, September 12th. Zacks Investment Research upgraded shares of Inogen from a “hold” rating to a “buy” rating and set a $131.00 price objective on the stock in a research report on Thursday, November 9th. Needham & Company LLC restated a “buy” rating and issued a $108.00 price objective on shares of Inogen in a research report on Friday, September 1st. Finally, BidaskClub cut shares of Inogen from a “buy” rating to a “hold” rating in a research report on Tuesday, December 5th. Four analysts have rated the stock with a hold rating, three have given a buy rating and one has issued a strong buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus price target of $103.14.
Inogen Company Profile
Inogen, Inc is a medical technology company. The Company develops, manufactures and markets portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The Company’s Inogen One systems concentrate the air around the patient to offer a single source of supplemental oxygen anytime, anywhere with a portable device.
Receive News & Ratings for Inogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen and related companies with MarketBeat.com's FREE daily email newsletter.